CME Presentations

Pancreatic Cancer


Presentations


Speakers

  • Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Attending Physician, Member

    Eileen M. O’Reilly, MD, is associate director for clinical research, David M. Rubenstein Center for Pancreatic Cancer; Winthrop Rockefeller Endowed Chair in Medical Oncology; and attending physician and member at Memorial Sloan Kettering Cancer Center in New York, and professor of medicine at Weill Cornell Medical College. Dr O’Reilly’s research and clinical activities focus on pancreatic and hepatobiliary malignancies. Her research initiatives include integrating molecular and genetic-based therapies into pancreatic cancer treatment, developing adjuvant and neoadjuvant therapies, and identifying biomarkers that may be used to select therapy. She is the principal investigator of multiple pancreatic cancer trials and has authored/co-authored more than 250 articles, editorials, and book chapters.
  • Andrew H. Ko, MD, FASCO

    Andrew H. Ko, MD, FASCO

    Andrew H. Ko, MD, FASCO

    Professor and Interim Chief (Oncology)

    Andrew H. Ko, MD, FASCO, is a professor of clinical medicine and interim chief of oncology in the Division of Hematology/Oncology, and a member of the Helen Diller Family Comprehensive Cancer Center, at the University of California, San Francisco, where he also chairs both the Cancer Center Scientific Protocol and Gastrointestinal Cancer Site Committees. Dr Ko’s primary clinical and research interests center on gastrointestinal malignancies, with an emphasis on pancreatic and gastroesophageal cancers. He has received research funding from the National Cancer Institute (NCI) and National Comprehensive Cancer Network (NCCN), has led numerous clinical trials, and is is currently participating in and/or co-leading several national initiatives for patients with pancreatic cancer.

CME Information

Treatment of Advanced Pancreatic Cancer: Navigating Current Choices and Appraising Promising New Directions


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Discuss clinical trial data and recommendations that outline appropriate treatments for patients with metastatic pancreatic cancer
  • Select therapy for patients with advanced pancreatic cancer based on patient, disease and toxicities, and treatment-emergent adverse events in patients with metastatic pancreatic cancer
  • Appraise emerging data that have changed practice or have potential to change practice for patients with metastatic pancreatic cancer

ACKNOWLEDGEMENT

This activity is supported by independent educational grants from Ipsen Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

TUITION

Complimentary

Jointly Accredited Provider Logo





JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

Live Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

DATE OF RELEASE/EXPIRATION

Live Internet Activity
Thursday, October 3, 2019 from 2:00 PM EDT - 3:00PM EDT

Enduring Material
The enduring material will be available from October 3, 2019 to April 3, 2020.

TARGET AUDIENCE

This activity is intended for medical oncologists, gastroenterologists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the management of patients with pancreatic cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Eileen O'Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head Hepatopancreaticobiliary & Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
Receipt of Intellectual Property Rights/Patent Holder (spouse): ARTICLES AND METHODS FOR PREVENTING AND TREATING DERMATOLOGIC ADVERSE EVENTS, identified by International Patent Application No. PCT/US2014/031545 filed on March 24, 2014, and priority application Serial No.: 61/804,907; Filed: March 25, 2013
Consulting Fees: Bioline, Celgene, CytomX, Jansen, Loxo, Merck, Pfizer, Silenseed, Sobi, Targovax, Twoxar
Consulting Fees (spouse): 3DMedcare, Agios, Alignmed, Amgen, Astra Zeneca, Bayer, Beigene, BMS, Boston Scientfic, Bridgebio, Carsgen, Celgene, Casi, Cipla, Daiichi, Debio, Delcath, Eisai, Exelixis, Flatiron, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Klus, Kyowa Kirin, LAM, Lilly, Merck, Mina, Novella, Onxeo, PCI Biotech, QED, Redhill, Sanofi, Servier, Sillajen, Tekmira, Twoxar, Vicus, Yakult, Yiviva
Contracted Research: ActaBiologica, Astra Zeneca, BMS, Celgene, Genentech, Halozyme, Mabvax, OncoQuest, Roche, Silenseed
Contracted Research (spouse): Agios, Array, Astra Zeneca, Bayer, BMS, Bridgebio, Casi, Exelixis, Genoscience, Halozyme, Incyte, Lilly, Novartis, Polaris, Puma, QED
Andrew H. Ko, MD, FASCO
Professor and Interim Chief (Oncology)
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
Consulting Fees: Gritstone (one-time advisory board) Erytech, Imugene (DSMC)
Contracted Research: Celgene, Merrimack, Halozyme, BMS, Merck, Roche/Genentech, Astellas, Apexigen, Abgenomics (funding for clinical trials paid directly to institution)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Agnes Lee Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Kim Jacobson, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.